Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
Although patients with 50% or higher PD-L1 with <i>KRAS</i> G12C, G12D, and other subtypes exhibited similar survival to <i>KRAS</i>wt, <i>KRAS</i> G12V was associated with significantly worse survival than <i>KRAS</i>wt and other <i>KRAS</i>m subtypes. All <i>KRAS</i>m should not be regarded as uniform predictors of ICI responsiveness, even with high PD-L1 expression; <i>KRAS</i> G12V tumors may have worse outcomes with ICI-based therapy and benefit from treatment intensification.
Authors
- Lova Sun (ORCID: https://orcid.org/0000-0002-5015-2964)
- Hossein Borghaei (ORCID: https://orcid.org/0000-0002-2577-4454)
- Jessica R. Bauman (ORCID: https://orcid.org/0000-0001-8691-0387)
- Elizabeth A. Handorf (ORCID: https://orcid.org/0000-0003-0445-8978)
- Charu Aggarwal (ORCID: https://orcid.org/0000-0002-3181-9460)
- Yunyun Zhou (ORCID: https://orcid.org/0000-0003-1689-8575)
Institutions
- Fox Chase Cancer Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100755
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Institutes of Health
- National Cancer Institute